Expert Review of Vaccines最新文献_第6页

Post-marketing surveillance for the safety of the quadrivalent human papillomavirus vaccine: a retrospective real-world study in China. 四价人乳头瘤病毒疫苗上市后安全性监测：中国的一项回顾性真实世界研究

IF 4.8 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-08-30 DOI: 10.1080/14760584.2025.2550972

Ruogu Meng, Rui Ma, Jianmei Wang, Peipei Liu, Zuoxiang Liu, Bingjie He, Zhike Liu, Yu Yang, Siyan Zhan

{"title":"Post-marketing surveillance for the safety of the quadrivalent human papillomavirus vaccine: a retrospective real-world study in China.","authors":"Ruogu Meng, Rui Ma, Jianmei Wang, Peipei Liu, Zuoxiang Liu, Bingjie He, Zhike Liu, Yu Yang, Siyan Zhan","doi":"10.1080/14760584.2025.2550972","DOIUrl":"https://doi.org/10.1080/14760584.2025.2550972","url":null,"abstract":"Background: The potential occurrence of autoimmune- and pregnancy-related adverse events with the quadrivalent human papillomavirus (4vHPV) vaccine has previously not been assessed in the real-world setting in China.Research design and methods: A retrospective active post-marketing surveillance of the 4vHPV vaccine has been conducted among Chinese women aged 20-45 years between January 2018 and March 2021 in the Ningbo city. Incidences of seven pre-specified autoimmune diseases diagnosed within 6 months after the 4vHPV vaccination were calculated. Cases of stillbirth and 23 congenital anomalies diagnosed within 3 months from birth in infants were collected in women with maternal exposure to the 4vHPV vaccine.Results: A total of 195,593 doses of the 4vHPV vaccine were administered to 76,212 women. New-onset cases of autoimmune diseases were diagnosed in 113 women, comprising 71 cases of Hashimoto's disease (130.84/100,000 person-years), 24 cases of Graves' disease (44.21/100,000 person-years), 1 case of optic neuritis (1.84/100,000 person-years), and 17 cases of uveitis (31.31/100,000 person-years). Among the 168 women with maternal exposure to the 4vHPV vaccine, five cases of congenital heart disease were observed in their infants.Conclusions: These findings confirm the favorable benefit/risk profile of the 4vHPV vaccine in Chinese women in the routine healthcare setting.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":"24 1","pages":"849-856"},"PeriodicalIF":4.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144948452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Potential public health impact of the adjuvanted RSVPreF3 vaccine in adults aged 60 years and older: results from a modeling study in India and Southeast Asia. RSVPreF3佐剂疫苗对60岁及以上成年人的潜在公共卫生影响：来自印度和东南亚的一项模拟研究的结果

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-06-26 DOI: 10.1080/14760584.2025.2523602

Ru Han, Jorge A Gomez, Chau Ngo Quy, Otavio Cintra, Desiree van Oorschot, Adriana Guzman-Holst

{"title":"Potential public health impact of the adjuvanted RSVPreF3 vaccine in adults aged 60 years and older: results from a modeling study in India and Southeast Asia.","authors":"Ru Han, Jorge A Gomez, Chau Ngo Quy, Otavio Cintra, Desiree van Oorschot, Adriana Guzman-Holst","doi":"10.1080/14760584.2025.2523602","DOIUrl":"10.1080/14760584.2025.2523602","url":null,"abstract":"Background: Respiratory syncytial virus (RSV) can cause acute respiratory infection (ARI) and severe symptoms in adults ≥60 years. The adjuvanted RSV prefusion F protein vaccine (adjuvanted RSVPreF3) offers protection to adults against RSV ARI and RSV lower respiratory tract disease (LRTD). We modeled the burden of RSV among adults ≥60 years in India and Southeast Asia, and the potential impact of RSV vaccination.Methods: A Markov model was adapted to the settings of India, Indonesia, Malaysia, the Philippines, Thailand, and Vietnam. RSV ARI cases, LRTD-associated hospitalizations, pneumonia, and deaths were tallied over a five-year period. Impact of adjuvanted RSVPreF3 vaccination with 30% and 70% coverage was assessed by calculation of incremental differences versus no vaccination.Results: A total of 73.9 million RSV ARI were projected to occur in adults ≥60 years living in the selected countries. Numbers of hospitalizations, pneumonia, and deaths were approximately 3.1 million, 2.9 million, and 294,000, respectively. Adjuvanted RSVPreF3 vaccination with a 30% coverage could prevent 8.6 million RSV ARI, 460,255 hospitalizations, 423,659 pneumonia, and 43,693 deaths over 5 years.Conclusions: The projected burden of RSV was substantial in India and Southeast Asia, and could greatly be alleviated through adjuvanted RSVPreF3 vaccination of adults ≥60 years.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"570-577"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144332678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pregnancy outcomes following unintentional exposure to TAK-003, a live-attenuated tetravalent dengue vaccine. 意外接触四价登革热减毒活疫苗 TAK-003 后的妊娠结局。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-03-27 DOI: 10.1080/14760584.2025.2480297

Martina Rauscher, Zeb Youard, Alice Faccin, Sanjay S Patel, Hang Pang, Olaf Zent

{"title":"Pregnancy outcomes following unintentional exposure to TAK-003, a live-attenuated tetravalent dengue vaccine.","authors":"Martina Rauscher, Zeb Youard, Alice Faccin, Sanjay S Patel, Hang Pang, Olaf Zent","doi":"10.1080/14760584.2025.2480297","DOIUrl":"10.1080/14760584.2025.2480297","url":null,"abstract":"Background: The tetravalent dengue vaccine TAK-003 is contraindicated during pregnancy. Pregnant women were excluded from TAK-003 clinical studies; however, some pregnancies occurred unintentionally.Research design and methods: This post-hoc analysis of phase 2 and 3 studies, evaluated pregnancy outcomes and neonatal adverse events (AEs) following unintentional vaccination during the time period ('exposure window') when women could be pregnant (within 44 days before last menstrual period until the outcome of pregnancy).Results: Of the 557 reported pregnancies, 38 (TAK-003, n = 28/375; placebo, n = 10/182) occurred inside the exposure window. Of these, 28 (TAK-003, n = 23; placebo, n = 5) resulted in live births, four resulted in elective terminations (TAK-003, n = 2; placebo, n = 2), five in spontaneous abortions (TAK-003, n = 3; placebo, n = 2) and one unknown outcome (placebo).Of the spontaneous abortions, there was no significant difference between TAK-003 and placebo recipients, or between those occurring within or outside the exposure window. Six participants who received TAK-003 in the exposure window and two neonates experienced serious AEs; none were considered TAK-003 related.Conclusions: This post-hoc analysis found no evidence of increased adverse pregnancy outcomes following unintentional TAK-003 vaccination occurring inside the exposure window compared with placebo.Clinical trial registration: The clinical trials from which data were extracted are registered at www.clinicaltrials.gov (identifiers are NCT02193087, NCT01511250, NCT02302066, NCT02425098, NCT03746015, NCT02747927, NCT03999996, NCT03423173, NCT03342898, NCT03771963, NCT04313244, NCT02948829, NCT035252119, NCT03341637).","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"221-229"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rebuilding vaccine confidence in Latin America and the Caribbean: strategies for the post-pandemic era. 重建拉丁美洲和加勒比对疫苗的信心：大流行后时代的战略。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-07-06 DOI: 10.1080/14760584.2025.2527327

Roberto Debbag, Julián Gallo, María L Ávila-Agüero, Claudia Beltran, José Brea-Del Castillo, Andrea Puentes, Silvia Enrique

{"title":"Rebuilding vaccine confidence in Latin America and the Caribbean: strategies for the post-pandemic era.","authors":"Roberto Debbag, Julián Gallo, María L Ávila-Agüero, Claudia Beltran, José Brea-Del Castillo, Andrea Puentes, Silvia Enrique","doi":"10.1080/14760584.2025.2527327","DOIUrl":"10.1080/14760584.2025.2527327","url":null,"abstract":"Introduction: Vaccine hesitancy in Latin America and the Caribbean (LAC) has a complex nature. It is shaped by socio-political, cultural, economic factors, and an influence of the COVID-19 pandemic on increasing hesitancy patterns. While LAC has maintained high vaccination coverage, it has experienced a decline over the past 10-years, further exacerbated by declining vaccine confidence during the pandemic, driven by misinformation, political polarization, and conspiracy theories.Areas covered: We review the impact of vaccine hesitancy across various stakeholders in LAC, focusing on healthcare professionals, parents, and community leaders, including data from studies conducted in Argentina and Colombia highlighting regional variations in hesitancy patterns. It describes the role of pediatricians in recommending vaccines, particularly in COVID-19 vaccines. The study explores how the rapid spread of misinformation, particularly through social media, exacerbated mistrust, and offers an overview of vaccine hesitancy trends in LAC during/after the pandemic.Expert opinion: While vaccine acceptance remains high among certain populations, communication strategies are essential to address concerns about vaccine safety. It is imperative to strengthen the relationship between health-providers and the public to mitigate misinformation and improve vaccine uptake. We propose seven strategic approaches for a comprehensive communication aimed at changing the public behavior about vaccines.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"615-623"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144552809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunogenicity and safety of meningococcal vaccines, MenACWY-CRM and 4CMenB, in groups at increased risk for meningococcal disease. 脑膜炎球菌疫苗MenACWY-CRM和4CMenB在脑膜炎球菌病高危人群中的免疫原性和安全性

IF 4.8 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-07-27 DOI: 10.1080/14760584.2025.2536079

Shravani Bobde, Chiranjiwi Bhusal, Catherine A Cosgrove, Woo-Yun Sohn

{"title":"Immunogenicity and safety of meningococcal vaccines, MenACWY-CRM and 4CMenB, in groups at increased risk for meningococcal disease.","authors":"Shravani Bobde, Chiranjiwi Bhusal, Catherine A Cosgrove, Woo-Yun Sohn","doi":"10.1080/14760584.2025.2536079","DOIUrl":"10.1080/14760584.2025.2536079","url":null,"abstract":"Introduction: Individuals with immunocompromising conditions (e.g. asplenia, complement deficiency, HIV infection) or with high exposure to Neisseria meningitidis (e.g. laboratory workers, those in outbreak settings) have an increased risk of meningococcal disease. Immunization with meningococcal serogroups ACWY (MenACWY) and serogroup B (MenB) vaccines is recommended for high-risk groups in many countries, although definitions of high-risk vary. There are not yet clinical data for the pentavalent meningococcal serogroups ABCWY (MenABCWY) vaccines in high-risk populations.Areas covered: This review examines studies conducted in high-risk groups with the component vaccines of GSK's MenABCWY vaccine, the 4-component MenB vaccine (4CMenB) and quadrivalent MenACWY CRM197-glycoconjugate vaccine (MenACWY-CRM). These component vaccines have been licensed for more than 10 years and are recommended in groups categorized as high risk.Expert opinion: The component vaccines of GSK's MenABCWY vaccine, 4CMenB and MenACWY-CRM, have demonstrated immunogenicity and safety in high-risk groups, including with concomitant or sequential vaccine administration. As expected, immunogenicity was reduced in patients with complement deficiencies, particularly those receiving eculizumab. Further data are required on meningococcal vaccination in high-risk groups for the future refinement of national and regional recommendations and to support proactive approaches to improve vaccine uptake in high-risk groups.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"656-667"},"PeriodicalIF":4.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144667471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Vaccination in adults at-increased risk of herpes zoster in Canada: insights from a multidisciplinary panel consensus. 加拿大带状疱疹风险增加的成人接种疫苗：来自多学科小组共识的见解。

IF 4.8 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-08-05 DOI: 10.1080/14760584.2025.2539884

Wayne Ghesquière, Dominique Tessier, Vivien Brown, Lyn Guenther, Derek Haaland, John Igoe, Kelly S MacDonald, Carolyn Whiskin

{"title":"Vaccination in adults at-increased risk of herpes zoster in Canada: insights from a multidisciplinary panel consensus.","authors":"Wayne Ghesquière, Dominique Tessier, Vivien Brown, Lyn Guenther, Derek Haaland, John Igoe, Kelly S MacDonald, Carolyn Whiskin","doi":"10.1080/14760584.2025.2539884","DOIUrl":"10.1080/14760584.2025.2539884","url":null,"abstract":"Background: Risk of herpes zoster (HZ) increases with age (notably at ≥50 years), with greater risk also apparent in immunocompromised populations. The use of the recombinant zoster vaccine (RZV) in adults aged ≥50 years is established in Canada. However, while licensed RZV use was expanded in 2021 to include individuals ≥18 years of age who are or will be at increased risk of HZ due to immunodeficiency or immunosuppression caused by known disease or therapy, there remains some uncertainty for clinicians regarding which patients should be offered vaccination.Research design and methods: To assist decision-making, a Canadian multidisciplinary panel was convened to develop guidance on the use of RZV in at-risk adults aged ≥18 years through a consensus approach, defined as ≥75% of the experts rating their agreement.Results: The panel concluded that RZV should be offered to all at-risk individuals aged ≥18 years who are or will be at increased risk of HZ due to disease or therapy, in line with the licensed indication. This includes those with chronic medical conditions at greater risk of HZ (e.g. COPD, diabetes). Decisions should be individualized based upon patient assessment and shared clinical decision-making. Where possible, the two-dose vaccine series should be given at the earliest opportunity.Conclusions: Findings from this expert consensus provide guidance on the use of RZV in individuals ≥18 years at increased risk of HZ. Our views complement updated national recommendations for immunocompromised patients issued in May 2025.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"769-781"},"PeriodicalIF":4.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144729101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world effectiveness of varicella vaccination in Guangzhou, China, 2017-2022: a matched case-control analysis. 2017-2022年中国广州水痘疫苗接种的实际有效性：匹配病例对照分析

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-07-24 DOI: 10.1080/14760584.2025.2536086

Junxi Li, Yong Huang, Siyu Chen, Danyang Song, Yulan Chen, Yikun Chang, Jinwei Chen, Wangjian Zhang, Jun Yuan, Zhicheng Du

{"title":"Real-world effectiveness of varicella vaccination in Guangzhou, China, 2017-2022: a matched case-control analysis.","authors":"Junxi Li, Yong Huang, Siyu Chen, Danyang Song, Yulan Chen, Yikun Chang, Jinwei Chen, Wangjian Zhang, Jun Yuan, Zhicheng Du","doi":"10.1080/14760584.2025.2536086","DOIUrl":"10.1080/14760584.2025.2536086","url":null,"abstract":"Background: China has yet to implement a nationwide two-dose vaccination strategy. This study assesses the real-world effectiveness of varicella vaccination in Guangzhou, where the policy recommends voluntary, self-funded administration of two doses of the live attenuated vaccine, to provide insights for optimizing vaccination strategies.Research design and methods: Using outbreak data from 2017 to 2022 across preschools, primary, and secondary schools, we employed a three-level matched case-control design (school, grade, and class) and applied conditional logistic regression to estimate the effectiveness of single-dose (VE1) and two-dose (VE2) vaccinations, incremental VE, and the effectiveness of emergency vaccination.Results: From 2017 to 2022, 1,058 varicella cases were included in the study, with a median age of 9.0 years. The effectiveness of a single-dose vaccine ranged from 45.8% to 46.7%, while the two-dose vaccine showed higher effectiveness (94.5% to 95.8%), with an incremental VE of 89.7% to 92.1%. VE1 decreased over time, whereas VE2 remained relatively high within five years after the booster dose, with the interval between doses having little effect on VE2. Emergency vaccination was effective for the first dose (78.0%-84.5%) and more effective for the second dose (87.2%-91.4%).Conclusions: Single-dose varicella vaccination provides limited protection, whereas the two-dose regimen enhances effectiveness.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"601-611"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144667435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pneumococcal vaccination willingness and influencing factors among older adults in Chongqing, China: a cross-sectional study based on the WHO's behavioral and social drivers of vaccination framework. 中国重庆老年人肺炎球菌疫苗接种意愿及其影响因素：基于WHO疫苗接种框架的行为和社会驱动因素的横断面研究

IF 4.8 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-09-22 DOI: 10.1080/14760584.2025.2564169

Jule Yang, Yanlin Cao, Luzhao Feng, Li Qi

{"title":"Pneumococcal vaccination willingness and influencing factors among older adults in Chongqing, China: a cross-sectional study based on the WHO's behavioral and social drivers of vaccination framework.","authors":"Jule Yang, Yanlin Cao, Luzhao Feng, Li Qi","doi":"10.1080/14760584.2025.2564169","DOIUrl":"10.1080/14760584.2025.2564169","url":null,"abstract":"Background: In the context of China's rapidly aging population and persistently low pneumococcal vaccine coverage, this study applied the Behavioral and Social Drivers (BeSD) framework to investigate the willingness and determinants of pneumococcal vaccination among adults aged 60 years and older in Chongqing.Research design and methods: We designed a cross-sectional survey targeting the community population and collected data on willingness toward pneumonia vaccination and associated demographic factors through questionnaires.Results: A total of 1,617 valid questionnaires were collected, 37.7% expressed willingness to receive pneumococcal vaccines. Higher vaccination willingness was associated with living in urban areas, having urban employee basic medical insurance, having an average monthly household income per capita below 2,000 CNY, being aware of pneumococcal vaccines, and showing interest in receiving vaccination information. Concerning the BeSD framework, concern over worsening health condition emerged as the primary driver, whereas perceived high vaccine costs and lack of awareness about vaccine were identified as major reasons for hesitancy.Conclusions: This study provides that future strategies should focus on addressing psychological determinants within old adults, alongside extensive promotion of knowledge regarding pneumonia vaccination, as well as exploring the impact of financial incentives on vaccination programs and payment strategies to enhance vaccination coverage.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"914-923"},"PeriodicalIF":4.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145085477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cost-effectiveness of strategies using preventive interventions to protect infants in Chile from respiratory syncytial virus. 使用预防干预措施保护智利婴儿免受呼吸道合胞体病毒感染战略的成本效益。

IF 4.8 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-10-02 DOI: 10.1080/14760584.2025.2562201

Rafael Bolanos, Rafael Araos, Cecilia Gonzalez, Dino Sepulveda, Juan Francisco Falconi, Ahuva Averin, Mark Atwood, Erin Quinn, Amy W Law, Diana Mendes

{"title":"Cost-effectiveness of strategies using preventive interventions to protect infants in Chile from respiratory syncytial virus.","authors":"Rafael Bolanos, Rafael Araos, Cecilia Gonzalez, Dino Sepulveda, Juan Francisco Falconi, Ahuva Averin, Mark Atwood, Erin Quinn, Amy W Law, Diana Mendes","doi":"10.1080/14760584.2025.2562201","DOIUrl":"10.1080/14760584.2025.2562201","url":null,"abstract":"Background: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract illness (LRTI; RSV-LRTI) among infants in Chile; young infants and infants born prematurely are at greatest risk.Research design and methods: A cohort model was developed to evaluate cost-effectiveness of strategies preventing RSV-LRTI in infants. Using the model, we calculated the economically justifiable price (EJP) of maternal RSVpreF vaccination (MV) versus no intervention and then evaluated the cost-effectiveness of MV (cost/dose assumed at EJP) with complementary use of monoclonal antibody nirsevimab for unprotected infants (MV+N) versus nirsevimab alone (NA) to prevent RSV-LRTI. Nirsevimab published price was $260.00; costs/prices reported in 2023 US$.Results: NA yielded 20,247 cases (hospital: 3,773, emergency ward: 16,474) and $57.2 million (M) in total costs (medical: $6.3 M, intervention: $48.7 M, indirect: $2.2 M). MV+N yielded 23,906 cases (hospital: 3,137, emergency ward: 20,769) and $28.7 M in costs (medical: $4.8 M, intervention: $21.7 M [RSVpreF assumed $75.77/dose; nirsevimab procured $260.00/dose], indirect: $2.2 M). With costs lower by $28.4 M and increased quality-adjusted life-years, MV+N would be cost-saving versus NA.Conclusions: RSVpreF vaccination among pregnant women along with nirsevimab for unprotected infants in Chile would be the most efficient use of resources, yielding substantial cost savings compared to use of nirsevimab alone.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"904-913"},"PeriodicalIF":4.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145074769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How to improve pertussis vaccination in pregnancy: a European expert review. 如何改善妊娠期百日咳疫苗接种：欧洲专家综述。

IF 5.5 3区医学

Expert Review of Vaccines Pub Date : 2025-12-01 Epub Date: 2025-03-14 DOI: 10.1080/14760584.2025.2473328

Adam Finn, Nicole Guiso, Carl Heinz Wirsing von König, Federico Martinón-Torres, Arto A Palmu, Paolo Bonanni, Pierre Bakhache, Helena C Maltezou, Pierre Van Damme

{"title":"How to improve pertussis vaccination in pregnancy: a European expert review.","authors":"Adam Finn, Nicole Guiso, Carl Heinz Wirsing von König, Federico Martinón-Torres, Arto A Palmu, Paolo Bonanni, Pierre Bakhache, Helena C Maltezou, Pierre Van Damme","doi":"10.1080/14760584.2025.2473328","DOIUrl":"10.1080/14760584.2025.2473328","url":null,"abstract":"Introduction: Pertussis vaccination in pregnancy is a safe and highly effective strategy to protect young infants against severe pertussis, but cases continue to occur. In November 2023, the authors of this paper met to discuss difficulties faced by pertussis vaccination programs in pregnant women in Europe, and the need and potential for new vaccines.Areas covered: We summarize current pertussis epidemiology, the status of pertussis vaccination in pregnancy in Europe, followed by a summary of the meeting on benefits of pertussis-only vaccines and pertussis vaccines with improved immunogenicity, including a review of available vaccines.Expert opinion: Ongoing surveillance and registers documenting vaccine uptake in pregnant women are important to monitor changes in pertussis epidemiology and estimated effectiveness of maternal pertussis vaccination programs in individual countries. While current programs have been effective, Tdap or Tdap-IPV combined vaccines are not the ideal choice but are the only vaccines available for pertussis immunization in pregnancy in Europe. Pertussis-only vaccine would avoid exposing women to unnecessary tetanus and diphtheria boosters in every pregnancy. Recombinant pertussis vaccines with higher immunogenicity could prolong passive immune protection against pertussis in young infants.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"175-182"},"PeriodicalIF":5.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0